KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Work In Process (2016 - 2018)

Teva Pharmaceutical Industries (TEVA) has disclosed Work In Process for 9 consecutive years, with $590.0 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Work In Process changed N/A year-over-year to $590.0 million, compared with a TTM value of $590.0 million through Dec 2018, changed N/A, and an annual FY2018 reading of $590.0 million, changed N/A over the prior year.
  • Work In Process was $590.0 million for Q4 2018 at Teva Pharmaceutical Industries, up from $183.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $605.0 million in Q2 2018 and bottomed at $183.0 million in Q3 2018.
  • Average Work In Process over 4 years is $308.7 million, with a median of $199.0 million recorded in 2016.
  • The sharpest move saw Work In Process decreased 4.62% in 2014, then rose 6.99% in 2016.
  • Year by year, Work In Process stood at $186.0 million in 2014, then changed by 0.0% to $186.0 million in 2015, then rose by 6.99% to $199.0 million in 2016, then skyrocketed by 196.48% to $590.0 million in 2018.
  • Business Quant data shows Work In Process for TEVA at $590.0 million in Q4 2018, $183.0 million in Q3 2018, and $605.0 million in Q2 2018.